

Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (Small Molecule, Biologics), By Drug, By Service, By Scale of Operation, By Workflow, By Application, By End Use, By Company, By Region, And Segment Forecasts, 2025 - 2030

https://marketpublishers.com/r/P3DE3B8E89A8EN.html

Date: February 2025

Pages: 150

Price: US\$ 5,950.00 (Single User License)

ID: P3DE3B8E89A8EN

Abstracts

medicine.

This report can be delivered to the clients within 3 Business Days

Pharmaceutical Contract Manufacturing Market Growth & Trends

The global pharmaceutical contract manufacturing market size is expected t%li%reach USD 224.51 billion by 2030, according t%li%a new report by Grand View Research, Inc. The market is anticipated t%li%grow at a CAGR of 9.84% from 2025 t%li%2030. Growth in the market can be attributed t%li%benefits offered t%li%pharmaceutical companies, such as cost efficiencies, the ability t%li%leverage contract manufacturing facilities t%li%streamline production, and the opportunity t%li%focus on core competencies. In addition, the market is driven by the increasing demand for biologics, biosimilars, high-potency active pharmaceutical ingredients (HPAPIs), and personalized

The expansion of pharmaceutical companies int%li%new product innovations has led t%li%the increased demand for contract manufacturing organization (CMO) services for clinical trials, packaging, and regulatory compliance. Technological integrations among CMOs, such as continuous manufacturing, automation, and Al-driven process optimization, are further propelling pharmaceutical production. These innovations enhance efficiency, reduce waste, and improve product quality and standards. The pharmaceutical contract manufacturing industry is expected t%li%experience continued growth during the forecast period, as CMO providers play a crucial role in



helping companies meet the regulatory requirements of the FDA, EMA, and ICH. Moreover, the growing demand for both branded and generic drugs is a significant factor in the expansion of the pharmaceutical contract manufacturing industry. As various generic drugs reach patent expiration, pharmaceutical companies are innovating new generic versions t%li%meet this demand. Hence, many of these pharmaceutical companies are relying on CMO services t%li%fulfill market needs efficiently and effectively.

In addition, regulation is one of the significant factors for pharmaceutical products that have fueled the demand for pharmaceutical contract manufacturing. The FDA plays a pivotal role in ensuring the safety and efficiency of pharmaceuticals in the market. Likewise, strategic partnerships and accelerating product launches drive market growth. For instance, in December 2024, Lonza mentioned the expansion of its service offering orally delivered biologic therapies t%li%support innovative capsule companies' unique development and manufacturing needs. The product launch will help patients explore innovative delivery solutions t%li%mitigate bioavailability challenges. Pharmaceutical Contract Manufacturing Market Report Highlights

The API manufacturing segment dominated the market with a share of 70.68% in 2024. Growth in the segment can be attributed t%li%increasing HPAPI production, rising demand for continuous API manufacturing, growing FDA approval for the market, and the launch of new products.

Based on product, the small molecule segment held the largest market share in 2024, which is attributed t%li%the increasing demand for generics, specialty drugs, and HPAPIs, and growing innovations of drugs have enhanced the requirement for CMO's efficiency, scalability, and regulatory compliance further driving the market growth.

The generics segment dominated the market in 2024 owing t%li%the increasing prevalence of chronic diseases, growing patent expirations, and rising demand for cost-efficient drugs.

Based on scale of operation, the batch segment dominated the market. It accounted for 88.88% in 2024, attributing t%li%various benefits such as batch production and major support for saving operational costs.

The commercial segment dominated the market in 2024. Growth in this segment can be attributed t%li%the increasing launch of various



products that help treat diseases.

The oncology segment held the largest market share in 2024 based on application. This segment is driven by increasing cancer incidences and new pharmaceutical drug requirements.

The pharmaceutical companies segment held the largest market share in 2024 based on end-use. Pharmaceutical companies utilize contract manufacturing t%li%lower costs, increase scalability, and speed up time-to-market. CMOs offer expertise in API synthesis, formulation, and regulatory compliance. In addition, outsourcing provides access t%li%advanced technologies, flexible production capacity, and optimized global supply chains.

The small company size segment dominated the market in 2024 due t%li%increasing employee strengths, facilities, and venture funding.

Asia Pacific is expected t%li%register the fastest growth rate of 10.80% CAGR over the forecast period. Due t%li%the rising number of pharmaceutical companies & contract manufacturing organizations in countries like Japan, China, and India, Asia Pacific will likely witness rapid growth over the estimated time. Furthermore, the availability of a skilled workforce within the region at a lower cost compared t%li%the U.S. is another factor that is anticipated t%li%propel the market growth.



Contents

CHAPTER 1. RESEARCH METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Service
 - 1.2.2. Product
 - 1.2.3. Drug
 - 1.2.4. Scale of Operation
 - 1.2.5. Workflow
 - 1.2.6. Application
 - 1.2.7. End Use
 - 1.2.8. Company Size
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased Database
 - 1.4.2. GVR's Internal Database
 - 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.5. Information Or Data Analysis
 - 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
 - 1.7.1. Commodity Flow Analysis
 - 1.7.2. Parent Market Analysis
- 1.8. List of Secondary Sources
- 1.9. List of Abbreviations
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights

CHAPTER 3. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET VARIABLES, TRENDS & SCOPE



- 3.1. Market Lineage Outlook
 - 3.1.1. Parent Market Outlook
 - 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
 - 3.2.1. Market Driver Analysis
 - 3.2.2. Market Restraint Analysis
- 3.3. Technological Advancements
- 3.4. Clinical trials volume analysis (2024)
- 3.5. Pharmaceutical Contract Manufacturing Market Analysis Tools
 - 3.5.1. Industry Analysis Porter's Five Analysis
 - 3.5.2. PESTEL Analysis
 - 3.5.3. COVID-19 Impact Analysis

CHAPTER 4. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE ESTIMATES & TREND ANALYSIS

- 4.1. Pharmaceutical Contract Manufacturing Market, By Service: Segment Dashboard
- 4.2. Pharmaceutical Contract Manufacturing Market, By Service: Movement Analysis
- 4.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Service, 2018 2030
- 4.4. API Manufacturing
- 4.4.1. API Manufacturing Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 4.5. Finished Drug Product Manufacturing
- 4.5.1. Finished Drug Product Manufacturing Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.5.2. Oral Solids
- 4.5.2.1. Oral Solids Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.5.3. Liquids
 - 4.5.3.1. Liquids Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.5.4. Topical
 - 4.5.4.1. Topical Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.5.5. Others
 - 4.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 4.6. Packaging Services
- 4.6.1. Packaging Services Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)



CHAPTER 5. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PRODUCT ESTIMATES & TREND ANALYSIS

- 5.1. Pharmaceutical Contract Manufacturing Market, By Product: Segment Dashboard
- 5.2. Pharmaceutical Contract Manufacturing Market, By Product: Movement Analysis
- 5.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Product, 2018 2030
- 5.4. Small Molecule
- 5.4.1. Small Molecule Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 5.5. Biologics
- 5.5.1. Biologics Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 5.5.2. Monoclonal Antibodies
- 5.5.2.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 5.5.3. Vaccines
- 5.5.3.1. Vaccines Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 5.5.4. Recombinant Proteins
- 5.5.4.1. Recombinant Proteins Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 5.5.5. Others
 - 5.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)

CHAPTER 6. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRUG ESTIMATES & TREND ANALYSIS

- 6.1. Pharmaceutical Contract Manufacturing Market, By Drug: Segment Dashboard
- 6.2. Pharmaceutical Contract Manufacturing Market, By Drug: Movement Analysis
- 6.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Drug, 2018 2030
- 6.4. Generics
- 6.4.1. Generics Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 6.5. Branded
 - 6.5.1. Branded Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)

CHAPTER 7. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SCALE OF OPERATION ESTIMATES & TREND ANALYSIS



- 7.1. Pharmaceutical Contract Manufacturing Market, By Scale of Operation: Segment Dashboard
- 7.2. Pharmaceutical Contract Manufacturing Market, By Scale of Operation: Movement Analysis
- 7.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Scale of Operation, 2018 2030
- 7.4. Batch
 - 7.4.1. Batch Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 7.5. Continuous
- 7.5.1. Continuous Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)

CHAPTER 8. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: WORKFLOW ESTIMATES & TREND ANALYSIS

- 8.1. Pharmaceutical Contract Manufacturing Market, By Workflow: Segment Dashboard
- 8.2. Pharmaceutical Contract Manufacturing Market, By Workflow: Movement Analysis
- 8.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Workflow, 2018 2030
- 8.4. Clinical
 - 8.4.1. Clinical Market, 2018 to 2030, (USD Million)
- 8.5. Commercial
 - 8.5.1. Commercial Market, 2018 to 2030, (USD Million)

CHAPTER 9. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: APPLICATION ESTIMATES & TREND ANALYSIS

- 9.1. Pharmaceutical Contract Manufacturing Market, By Application: Segment Dashboard
- 9.2. Pharmaceutical Contract Manufacturing Market, By Application: Movement Analysis
- 9.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Application, 2018 - 2030
- 9.4. Oncology
 - 9.4.1. Oncology Market, 2018 to 2030, (USD Million)
- 9.5. Infectious Diseases
 - 9.5.1. Infectious Diseases Market, 2018 to 2030, (USD Million)
- 9.6. Neurological Disorders
 - 9.6.1. Neurological Disorders Market, 2018 to 2030, (USD Million)
- 9.7. Cardiovascular Disease



- 9.7.1. Cardiovascular Disease Market, 2018 to 2030, (USD Million)
- 9.8. Metabolic Disorders
- 9.8.1. Metabolic Disorders Market, 2018 to 2030, (USD Million)
- 9.9. Autoimmune Diseases
- 9.9.1. Autoimmune Diseases Market, 2018 to 2030, (USD Million)
- 9.10. Respiratory Diseases
 - 9.10.1. Respiratory Diseases Market, 2018 to 2030, (USD Million)
- 9.11. Ophthalmology
 - 9.11.1. Ophthalmology Market, 2018 to 2030, (USD Million)
- 9.12. Gastrointestinal Disorders
- 9.12.1. Gastrointestinal Disorders Market, 2018 to 2030, (USD Million)
- 9.13. Hormonal Disorders
 - 9.13.1. Hormonal Disorders Market, 2018 to 2030, (USD Million)
- 9.14. Hematological Disorders
- 9.14.1. Hematological Disorders Market, 2018 to 2030, (USD Million)
- 9.15. Others
 - 9.15.1. Others Market, 2018 to 2030, (USD Million)

CHAPTER 10. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: END USE ESTIMATES & TREND ANALYSIS

- 10.1. Pharmaceutical Contract Manufacturing Market, By End Use: Segment Dashboard
- 10.2. Pharmaceutical Contract Manufacturing Market, By End Use: Movement Analysis
- 10.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By End Use, 2018 2030
- 10.4. Pharmaceutical Companies
- 10.4.1. Pharmaceutical Companies Market, 2018 to 2030, (USD Million)
- 10.5. Biotechnology Companies
- 10.5.1. Biotechnology Companies Market, 2018 to 2030, (USD Million)

CHAPTER 11. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY SIZE ESTIMATES & TREND ANALYSIS

- 11.1. Pharmaceutical Contract Manufacturing Market, By Company Size: Segment Dashboard
- 11.2. Pharmaceutical Contract Manufacturing Market, By Company Size: Movement Analysis
- 11.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Company Size, 2018 2030



- 11.4. Small
 - 11.4.1. Small Market, 2018 to 2030, (USD Million)
- 11.5. Medium
 - 11.5.1. Medium Market, 2018 to 2030, (USD Million)
- 11.6. Large
 - 11.6.1. Large Market, 2018 to 2030, (USD Million)

CHAPTER 12. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

- 12.1. Regional Market Share Analysis, 2024 & 2030
- 12.2. Regional Market Dashboard
- 12.3. Global Regional Market Snapshot
- 12.4. North America
 - 12.4.1. North America Market Estimates and Forecasts, 2018 2030 (USD Million)
 - 12.4.2. U.S
 - 12.4.2.1. Key Country Dynamics
 - 12.4.2.2. Competitive Scenario
 - 12.4.2.3. Regulatory Framework
 - 12.4.2.4. U.S. Market Estimates and Forecasts, 2018 2030 (USD Million)
 - 12.4.3. Canada
 - 12.4.3.1. Key Country Dynamics
 - 12.4.3.2. Competitive Scenario
 - 12.4.3.3. Regulatory Framework
 - 12.4.3.4. Canada Market Estimates and Forecasts, 2018 2030 (USD Million)
 - 12.4.4. Mexico
 - 12.4.4.1. Key Country Dynamics
 - 12.4.4.2. Competitive Scenario
 - 12.4.4.3. Regulatory Framework
 - 12.4.4.4. Mexico Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.5. Europe
 - 12.5.1. Europe Market Estimates and Forecasts, 2018 2030 (USD Million)
 - 12.5.2. UK
 - 12.5.2.1. Key Country Dynamics
 - 12.5.2.2. Competitive Scenario
 - 12.5.2.3. Regulatory Framework
 - 12.5.2.4. UK Market Estimates and Forecasts, 2018 2030 (USD Million)
 - 12.5.3. Germany
 - 12.5.3.1. Key Country Dynamics



- 12.5.3.2. Competitive Scenario
- 12.5.3.3. Regulatory Framework
- 12.5.3.4. Germany Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.5.4. France
 - 12.5.4.1. Key Country Dynamics
 - 12.5.4.2. Competitive Scenario
- 12.5.4.3. Regulatory Framework
- 12.5.4.4. France Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.5.5. Italy
 - 12.5.5.1. Key Country Dynamics
 - 12.5.5.2. Competitive Scenario
 - 12.5.5.3. Regulatory Framework
 - 12.5.5.4. Italy Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.5.6. Spain
- 12.5.6.1. Key Country Dynamics
- 12.5.6.2. Competitive Scenario
- 12.5.6.3. Regulatory Framework
- 12.5.6.4. Spain Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.5.7. Denmark
- 12.5.7.1. Key Country Dynamics
- 12.5.7.2. Competitive Scenario
- 12.5.7.3. Regulatory Framework
- 12.5.7.4. Denmark Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.5.8. Sweden
 - 12.5.8.1. Key Country Dynamics
 - 12.5.8.2. Competitive Scenario
 - 12.5.8.3. Regulatory Framework
 - 12.5.8.4. Sweden Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.5.9. Norway
 - 12.5.9.1. Key Country Dynamics
 - 12.5.9.2. Competitive Scenario
 - 12.5.9.3. Regulatory Framework
 - 12.5.9.4. Norway Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.6. Asia Pacific
 - 12.6.1. Asia Pacific Market Estimates and Forecasts, 2018 2030 (USD Million)
 - 12.6.2. Japan
 - 12.6.2.1. Key Country Dynamics
 - 12.6.2.2. Competitive Scenario
 - 12.6.2.3. Regulatory Framework



- 12.6.2.4. Japan Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.6.3. China
- 12.6.3.1. Key Country Dynamics
- 12.6.3.2. Competitive Scenario
- 12.6.3.3. Regulatory Framework
- 12.6.3.4. China Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.6.4. India
 - 12.6.4.1. Key Country Dynamics
 - 12.6.4.2. Competitive Scenario
 - 12.6.4.3. Regulatory Framework
 - 12.6.4.4. India Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.6.5. Thailand
- 12.6.5.1. Key Country Dynamics
- 12.6.5.2. Competitive Scenario
- 12.6.5.3. Regulatory Framework
- 12.6.5.4. Thailand Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.6.6. South Korea
 - 12.6.6.1. Key Country Dynamics
- 12.6.6.2. Competitive Scenario
- 12.6.6.3. Regulatory Framework
- 12.6.6.4. South Korea Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.6.7. Australia
- 12.6.7.1. Key Country Dynamics
- 12.6.7.2. Competitive Scenario
- 12.6.7.3. Regulatory Framework
- 12.6.7.4. Australia Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.7. Latin America
- 12.7.1. Latin America Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.7.2. Brazil
 - 12.7.2.1. Key Country Dynamics
 - 12.7.2.2. Competitive Scenario
 - 12.7.2.3. Regulatory Framework
 - 12.7.2.4. Brazil Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.7.3. Argentina
- 12.7.3.1. Key Country Dynamics
- 12.7.3.2. Competitive Scenario
- 12.7.3.3. Regulatory Framework
- 12.7.3.4. Argentina Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.8. MEA



- 12.8.1. MEA Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.8.2. South Africa
 - 12.8.2.1. Key Country Dynamics
 - 12.8.2.2. Competitive Scenario
 - 12.8.2.3. Regulatory Framework
- 12.8.2.4. South Africa Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.8.3. Saudi Arabia
 - 12.8.3.1. Key Country Dynamics
 - 12.8.3.2. Competitive Scenario
 - 12.8.3.3. Regulatory Framework
- 12.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.8.4. UAE
 - 12.8.4.1. Key Country Dynamics
 - 12.8.4.2. Competitive Scenario
- 12.8.4.3. Regulatory Framework
- 12.8.4.4. UAE Market Estimates and Forecasts, 2018 2030 (USD Million)
- 12.8.5. Kuwait
 - 12.8.5.1. Key Country Dynamics
- 12.8.5.2. Competitive Scenario
- 12.8.5.3. Regulatory Framework
- 12.8.5.4. Kuwait Market Estimates and Forecasts, 2018 2030 (USD Million)

CHAPTER 13. COMPETITIVE LANDSCAPE

- 13.1. Market Participant Categorization
- 13.2. Company Market Share Analysis, 2023/24
- 13.3. Company Profiles
 - 13.3.1. AbbVie Contract Manufacturing
 - 13.3.1.1. Company Overview
 - 13.3.1.2. Financial Performance
 - 13.3.1.3. Service Benchmarking
 - 13.3.1.4. Strategic Initiatives
 - 13.3.2. Almac Group
 - 13.3.2.1. Company Overview
 - 13.3.2.2. Financial Performance
 - 13.3.2.3. Service Benchmarking
 - 13.3.2.4. Strategic Initiatives
 - 13.3.3. Boehringer Ingelheim BioXcellence
 - 13.3.3.1. Company Overview



- 13.3.3.2. Financial Performance
- 13.3.3.3. Service Benchmarking
- 13.3.3.4. Strategic Initiatives
- 13.3.4. Catalent
 - 13.3.4.1. Company Overview
 - 13.3.4.2. Financial Performance
 - 13.3.4.3. Service Benchmarking
 - 13.3.4.4. Strategic Initiatives
- 13.3.5. Dr. Reddy's Laboratories
- 13.3.5.1. Company Overview
- 13.3.5.2. Financial Performance
- 13.3.5.3. Service Benchmarking
- 13.3.5.4. Strategic Initiatives
- 13.3.6. Fareva
- 13.3.6.1. Company Overview
- 13.3.6.2. Financial Performance
- 13.3.6.3. Service Benchmarking
- 13.3.6.4. Strategic Initiatives
- 13.3.7. Fujifilm Diosynth Biotechnologies
 - 13.3.7.1. Company Overview
 - 13.3.7.2. Financial Performance
 - 13.3.7.3. Service Benchmarking
 - 13.3.7.4. Strategic Initiatives
- 13.3.8. Jubilant HollisterStier
 - 13.3.8.1. Company Overview
 - 13.3.8.2. Financial Performance
 - 13.3.8.3. Service Benchmarking
 - 13.3.8.4. Strategic Initiatives
- 13.3.9. Lonza Group
 - 13.3.9.1. Company Overview
 - 13.3.9.2. Financial Performance
 - 13.3.9.3. Service Benchmarking
 - 13.3.9.4. Strategic Initiatives
- 13.3.10. Patheon (Thermo Fisher Scientific)
 - 13.3.10.1. Company Overview
 - 13.3.10.2. Financial Performance
 - 13.3.10.3. Service Benchmarking
 - 13.3.10.4. Strategic Initiatives
- 13.3.11. Pfizer CentreOne



- 13.3.11.1. Company Overview
- 13.3.11.2. Financial Performance
- 13.3.11.3. Service Benchmarking
- 13.3.11.4. Strategic Initiatives
- 13.3.12. Prakruti Life Science
 - 13.3.12.1. Company Overview
 - 13.3.12.2. Financial Performance
 - 13.3.12.3. Service Benchmarking
 - 13.3.12.4. Strategic Initiatives
- 13.3.13. Recipharm
 - 13.3.13.1. Company Overview
 - 13.3.13.2. Financial Performance
 - 13.3.13.3. Service Benchmarking
 - 13.3.13.4. Strategic Initiatives
- 13.3.14. Samsung Biologics
 - 13.3.14.1. Company Overview
 - 13.3.14.2. Financial Performance
 - 13.3.14.3. Service Benchmarking
 - 13.3.14.4. Strategic Initiatives
- 13.3.15. Siegfried Holding AG
 - 13.3.15.1. Company Overview
 - 13.3.15.2. Financial Performance
 - 13.3.15.3. Service Benchmarking
 - 13.3.15.4. Strategic Initiatives
- 13.3.16. Vetter Pharma
 - 13.3.16.1. Company Overview
 - 13.3.16.2. Financial Performance
 - 13.3.16.3. Service Benchmarking
 - 13.3.16.4. Strategic Initiatives
- 13.3.17. WuXi AppTec
 - 13.3.17.1. Company Overview
 - 13.3.17.2. Financial Performance
 - 13.3.17.3. Service Benchmarking
 - 13.3.17.4. Strategic Initiatives



I would like to order

Product name: Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By

Product (Small Molecule, Biologics), By Drug, By Service, By Scale of Operation, By Workflow, By Application, By End Use, By Company, By Region, And Segment

Forecasts, 2025 - 2030

Product link: https://marketpublishers.com/r/P3DE3B8E89A8EN.html

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P3DE3B8E89A8EN.html